 |
|
Jefferson scientists find protein helps pancreatic cancer cells evade immune system and spread
January 11, 2008A protein that helps prevent a woman's body from rejecting a fetus may also play an important role in enabling pancreatic cancer cells to evade detection by the immune system, allowing them to spread in the body.
Researchers at Jefferson's Kimmel Cancer Center in Philadelphia found that the metastatic cancer cells in the lymph nodes of patients with pancreatic cancer produce enough of the protein, IDO, to essentially wall-off the immune system's T-cells and recruit cells that suppress the immune system's response to the tumor. The findings might mean not only a better way to detect pancreatic cancer spreading to lymph nodes, but also could enhance tumor immune therapy strategies against the fast-moving, deadly disease.
According to Jonathan Brody, Ph.D., assistant professor of Surgery at Jefferson Medical College of Thomas Jefferson University, one way that metastatic cancer cells can survive in nearby lymph nodes is by avoiding the immune system. Evidence from studies by scientists looking at other cancers has indicated that IDO (indolamine 2'3 dioxygenase) is critical to regulating the "immune environment." The Jefferson scientists wanted to know if metastatic pancreatic cancer cells residing in the lymph nodes expressed IDO to avoid being found, and if so, could they target this enzyme with available drugs to prevent the cancer cells from hiding from the immune system.
Dr. Brody, Charles Yeo, M.D., Samuel D. Gross Professor and chair of Surgery at Jefferson Medical College and their co-workers analyzed IDO expression in 14 lymph nodes to which pancreatic cancer cells had spread and compared them to the primary tumors that had not spread in the same patients. In every case, they found greater expression of the IDO protein in the cancerous lymph nodes. They also looked at three cases of lymph node-negative pancreatic cancers, finding little IDO present.
Scientists know that IDO shuts off tryptophan production in T-cells, putting them in a resting state, and recruits a different type of immune cell called T-regulatory cells, which can inhibit the immune system. "If cells are escaping the primary tumor and going into another environment such as the lymph nodes, what are they doing to evade detection by the immune system?" says Dr. Brody. "These data point to the fact that IDO may play a role in helping cancer cells avoid the immune system." His team reported its findings at the recent meeting of the Southern Surgical Association in Hot Springs, VA. The results have been accepted for publication in the Journal of the American College of Surgeons.
The group also examined pancreatic cancer cell lines in the laboratory for IDO expression. Using antibodies to IDO, they didn't find any IDO expression until they treated the cells with interferon to mimic the conditions in the lymph nodes. The tumor cells were then able to make the enzyme.
Whether or not the cancer has spread to the lymph nodes can affect a patient's prognosis, particularly after surgery. While scientists know a great deal about how a pancreatic cancer develops from a pre-cancerous growth into a cancer, they still don't have a clear understanding of how it progresses from a primary cancer to metastatic disease. IDO, Dr. Brody says, may play an important part in the process.
"The immune system appears to have a balance that can allow cancer cells to grow but also can detect and destroy them, Brody explains. "While IDO is crucial to regulating this balance, too much IDO tips the balance toward an immune suppression, supporting cancer growth."
Dr. Brody notes that IDO inhibitors are available clinically, and these could in theory be used with chemotherapy or perhaps other forms of immune therapy against pancreatic cancer. An inhibitor might be able to activate T-cells to kill cancer cells, for example. "Presumably we could give IDO inhibitors up front to patients who we know are lymph node-positive to try to reduce the cancer and possibly convert them to surgical candidates," he explains.
Pancreatic cancer, the fourth-leading cause of cancer death in this country, takes some 33,000 lives a year. The disease is difficult to treat, particularly because it is frequently detected after it has spread to other areas on the body. Only 5 percent of all individuals with pancreatic cancer live for five years after diagnosis, and approximately 25 percent of those diagnosed with pancreatic cancer who undergo successful surgical removal of their disease live at least that long. But recent figures give new hope: of those who live for five years after surgical resection, some 55 percent will be alive at least another five years.
Thomas Jefferson University
Dr. Brody, Charles Yeo, M.D., Samuel D. Gross Professor and chair of Surgery at Jefferson Medical College and their co-workers analyzed IDO expression in 14 lymph nodes to which pancreatic cancer cells had spread and compared them to the primary tumors that had not spread in the same patients. In every case, they found greater expression of the IDO protein in the cancerous lymph nodes. They also looked at three cases of lymph node-negative pancreatic cancers, finding little IDO present.
Scientists know that IDO shuts off tryptophan production in T-cells, putting them in a resting state, and recruits a different type of immune cell called T-regulatory cells, which can inhibit the immune system. "If cells are escaping the primary tumor and going into another environment such as the lymph nodes, what are they doing to evade detection by the immune system?" says Dr. Brody. "These data point to the fact that IDO may play a role in helping cancer cells avoid the immune system." His team reported its findings at the recent meeting of the Southern Surgical Association in Hot Springs, VA. The results have been accepted for publication in the Journal of the American College of Surgeons.
The group also examined pancreatic cancer cell lines in the laboratory for IDO expression. Using antibodies to IDO, they didn't find any IDO expression until they treated the cells with interferon to mimic the conditions in the lymph nodes. The tumor cells were then able to make the enzyme.
Whether or not the cancer has spread to the lymph nodes can affect a patient's prognosis, particularly after surgery. While scientists know a great deal about how a pancreatic cancer develops from a pre-cancerous growth into a cancer, they still don't have a clear understanding of how it progresses from a primary cancer to metastatic disease. IDO, Dr. Brody says, may play an important part in the process.
"The immune system appears to have a balance that can allow cancer cells to grow but also can detect and destroy them, Brody explains. "While IDO is crucial to regulating this balance, too much IDO tips the balance toward an immune suppression, supporting cancer growth."
Dr. Brody notes that IDO inhibitors are available clinically, and these could in theory be used with chemotherapy or perhaps other forms of immune therapy against pancreatic cancer. An inhibitor might be able to activate T-cells to kill cancer cells, for example. "Presumably we could give IDO inhibitors up front to patients who we know are lymph node-positive to try to reduce the cancer and possibly convert them to surgical candidates," he explains.
Pancreatic cancer, the fourth-leading cause of cancer death in this country, takes some 33,000 lives a year. The disease is difficult to treat, particularly because it is frequently detected after it has spread to other areas on the body. Only 5 percent of all individuals with pancreatic cancer live for five years after diagnosis, and approximately 25 percent of those diagnosed with pancreatic cancer who undergo successful surgical removal of their disease live at least that long. But recent figures give new hope: of those who live for five years after surgical resection, some 55 percent will be alive at least another five years.
Thomas Jefferson University
Pancreatic Cancer Current Events and Pancreatic Cancer News RSSDiscovery offers potential new pancreatic cancer treatment
Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein.
Hepatitis B does not increase risk for pancreatic cancer
A Henry Ford Hospital study found that hepatitis B does not increase the risk for pancreatic cancer - and that only age is a contributing factor.
M. D. Anderson examines use of toad venom in cancer treatment
Huachansu, a Chinese medicine that comes from the dried venom secreted by the skin glands of toads, has tolerable toxicity levels, even at doses eight times those normally administered, and may slow disease progression in some cancer patients, say researchers from The University of Texas M. D. Anderson Cancer Center.
Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy
For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease.
Endothelin-1 inhibitors in chronic pancreatitis
Fibrosis is a key feature of chronic pancreatitis and pancreatic cancer. The extensive deposition of extracellular matrix proteins fosters the development of an exocrine and endocrine organ insufficiency, and accelerates progression of the tumour.
Autoimmune response can induce pancreatic tumor rejection
Immune responses are capable of killing tumors before they can be directed toward normal body tissue, according to new scientific findings published in Cancer Research, a journal of the American Association for Cancer Research.
MicroRNAs circulating in blood show promise as biomarkers to detect pancreatic cancer
A blood test for small molecules abnormally expressed in pancreatic cancer may be a promising route to early detection of the disease.
Blood-flow metabolism mismatch predicts pancreatic tumor aggressiveness
Researchers from Turku, Finland, have identified a blood-flow glucose consumption mismatch that predicted pancreatic tumor aggressiveness, according to results of a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Taking the Needle's Sting Out of Diabetes
Found in 30% of all human cancer tumors, the Ras protein literally "drives cells crazy," says Prof. Yoel Kloog, the dean of the Faculty of Life Sciences at Tel Aviv University. Prof. Kloog was the first in the world to develop an effective anti-Ras drug against pancreatic cancer, currently in clinical trials.
Heavy drinkers face significantly increased cancer risk
Heavy drinkers of beer and spirits face a much higher risk of developing cancer than the population at large, says a group of Montreal epidemiologists and cancer researchers.
More Pancreatic Cancer Current Events and Pancreatic Cancer News Articles
 |
Pancreatic Cancer (M.D. Anderson Solid Tumor Oncology Series) by Andrew M. Lowy (Editor), Steven D. Leach (Editor), Philip Philip (Editor) Since the previous M.D. Anderson Solid Tumor Oncology Series publication on pancreatic cancer, there have been major advances in our understanding of molecular events which underlie pancreatic cancer development, both in the sporadic and inherited forms. We have seen the development of the first mouse models that accurately recapitulate features of the human disease. Several landmark clinical trials in both resectable and metastatic pancreatic cancer have been completed, raising new questions about the standard of care in this disease. Finally, the era of targeted biologic therapies has engendered new excitement about the prospects of more rapid progress in understanding and successfully treating this dreadful disease. Therefore, it is an appropriate time to review these important... |
 |
100 Q&A About Pancreatic Cancer (100 Questions & Answers) by Joanne Frankel Kelvin Eileen O'Reilly (Author) EMPOWER YOURSELF! Whether you’re a newly diagnosed pancreatic cancer patient, a survivor, or a friend or relative of someone with pancreatic cancer, this book offers help. The only text to provide a doctor’s and patient’s view, 100 Questions & Answers About Pancreatic Cancer gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. The authors, a medical oncologist and a nurse with 25 years of experience with cancer patients, provide a comprehensive, step-by-step discussion of what you can expect in the diagnosis and treatment of pancreatic cancer, while patient commentaries provide a real-life understanding of what these steps might mean for your day-to-day life. This book is an... |
 |
100 Questions & Answers About Pancreatic Cancer, Second Edition by Eileen O'Reilly (Author), Joanne Frankel Kelvin (Author) Whether you re a newly diagnosed pancreatic cancer patient, a survivor, or a friend or relative of someone with pancreatic cancer, this book offers help. The only text to provide a doctor s and patient s view, 100 Questions & Answers About Pancreatic Cancer, Second Edition gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. The authors, a medical oncologist and a nurse with 25 years of experience with cancer patients, provide a comprehensive, step-by-step discussion of what you can expect in the diagnosis and treatment of pancreatic cancer, while patient commentaries provide a real-life understanding of what these steps might mean for your day-to-day life. This book is an invaluable... |
 |
My Journey With Pancreatic Cancer by Calvin Rains (Author) This book is shared to help all understand the cancer affecting the pancreas which is a vital organ in the digestion of food. Pancreatic cancer is one of the most deadly of cancers affecting the human body. Less than 5% of those diagnosed with Pancreatic Cancer survive the first year.This book is intended to help the patient, their families, and friends to understand the dangers and possible treatments. It is vital that the patient and their families understand the importance of choices of treatment and the possible side effects.This is basically a diary of one patient who has been able to survive five (5) years at this writing. The road can be challenging, but healing is possible if discovered and treated quickly. This book will help the patient and their families to better deal with... |
 |
Pancreatic Cancer by Daniel D. Von Hoff (Editor) (Author) Praise for the book “An outstanding text covering all aspects of pancreatic cancer, from embryology through genetics and pathology, and including all avenues of treatment. There are 112 internationally recognized authors, the book is marvelously illustrated, and is a must for all scientists and clinicians interested in neoplasms of the pancreas. It is currently the most up-to-date and complete text on pancreatic cancer available.” -- John L. Cameron, MD The Alfred Blalock Distinguished Service Professor The Johns Hopkins University School of Medicine |
 |
Pancreatic Cancer: Current and Emerging Trends in Detection and Treatment (Cancer and Modern Science) by Amy Sterling Casil (Author) |
 |
Beating Pancreatic Cancer Together T-shirt Large White by Shop Zeus |
 |
The Official Patient's Sourcebook on Pancreatic Cancer: A Revised and Updated Directory for the Internet Age by Icon Health Publications (Author) This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to pancreatic cancer (also Cancer pancreas; Pancreatic cancer), from the essentials to the most advanced areas of research. The title of this book includes the word official. This reflects the fact that the sourcebook draws from public, academic, government, and peer-reviewed research. Selected readings from various agencies are reproduced to give you some of the latest official information available to date on pancreatic cancer. Given patients' increasing sophistication... |
 |
Clearly Charming Purple Ribbon - Pancreatic Cancer Awareness Italian Charm 18k Gold and Enamel by Casa D'Oro by Clearly Charming Show your support for those people who are affected and for a cure. This charm is made by Casa D'Oro with 18k gold and baked enamel. It will make a great addition to your Italian charm bracelet or a perfect personalized gift. Commemorate special occasions, capture memorable moments, or simply show support for those affected by creating your own original Italian charm bracelet. Add Clearly Charming premium quality interlocking modular Italian charm links to your Italian Charm Bracelet and create your own memory bracelet. |
 |
Pancreatic Cancer (Recent Results in Cancer Research) by H. Riess (Editor), A. Goerke (Editor), H. Oettle (Editor) Although pancreatic cancer is one of the most serious forms of cancers, the outlook for patients could be improved. The lack of clinical symptoms of early, surgically removable disease most often limits curative treatment options. The aggressive tumor cell biology, leading to a locally advanced nature of the disease and to early metastases, allows curative resection in only 20% of patients at the time of diagnosis. Patients are therefore often faced with a dreadful prognosis from a state of almost full physical health. Furthermore, because there is a high recurrence rate after curative resection, treatment of this tumor entity becomes a great challenge. This book gives insight into the current understanding of the management of pancreatic cancer and considers recent findings in... |
| © 2009 BrightSurf.com |